Greenwich LifeSciences, Inc.
NASDAQ:GLSI
9.98 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Gross Profit
| 0 | -0.004 | -0.004 | -0.004 | -0.004 | -0.004 | -0.004 | -0.004 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 12.952 | 7.699 | 6.476 | 3.56 | 1.058 | 2.606 | 1.27 | 1.223 |
| General & Administrative Expenses
| 3.06 | 1.629 | 1.565 | 1.038 | 0.806 | 0.819 | 0.42 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.06 | 1.629 | 1.565 | 1.038 | 0.806 | 0.819 | 0.42 | 0.347 |
| Other Expenses
| 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 16.012 | 9.328 | 8.04 | 4.598 | 1.864 | 3.425 | 1.69 | 1.57 |
| Operating Income
| -16.012 | -9.328 | -8.04 | -4.598 | -1.864 | -3.425 | -1.69 | -1.573 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.223 | 0.436 | 0.215 | 0.027 | 0.001 | 0 | 0 | 0 |
| Income Before Tax
| -15.789 | -8.892 | -7.825 | -4.571 | -1.863 | -3.425 | -1.69 | -1.573 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.215 | -0.027 | -0.001 | 0 | -0.158 | 0 |
| Net Income
| -15.789 | -8.892 | -7.61 | -4.543 | -1.862 | -3.425 | -1.69 | -1.573 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.21 | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EPS Diluted
| -1.21 | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EBITDA
| -16.012 | -9.324 | -8.037 | -4.594 | -1.86 | -3.422 | -1.686 | -1.57 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |